Natixis Bleichroeder Initiates Coverage on Gen-Probe (GPRO) with a Buy
More News related to GPRO
- Jefferies & Co Initiates Coverage on Biotechnology and Drugs/Medical Supply Stocks
- Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2009 Earnings Conference Call
- DiagnoCure announces fourth quarter 2009 and year-end results
- Gen-Probe to Webcast Presentation at the 28th Annual J.P. Morgan Healthcare Conference
- DiagnoCure to host Q4 2009 and full year earnings conference call and webcast
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
Natixis Bleichroeder initiates coverage on Gen-Probe (Nasdaq: GPRO) with a Buy. Price target $49.
To see more analyst ratings on GPRO Click Here.
Gen-Probe Incorporated develops, manufactures, and markets nucleic acid probe-based products used for the clinical diagnosis of human diseases, and for screening donated human blood in North America and internationally.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
